3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street

Motley Fool2022-03-30

KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

559

Report

Comment（34）

Bspn
·2022-03-31
Ok
Reply
Like
Report
saral
·2022-03-31
Wow
Reply
1
Report
Jess261
·2022-03-31
okay
Reply
Like
Report
WaiSiong81
·2022-03-31
👍
Reply
2
Report
seojun
·2022-03-31
Green energy seems like way to go!
Reply
2
Report
Vincent1968
·2022-03-31
Like
Reply
3
Report
Rick13
·2022-03-31
Like
Reply
3
Report
xiaobaii
·2022-03-31
like & comment please
Reply
4
Report
bostonxsgp
·2022-03-31
meh
Reply
5
Report
fysx49
·2022-03-31
Market start recovering
Reply
4
Report
Success88
·2022-03-31
Yes great
Reply
4
Report
SS3006
·2022-03-31
👍
Reply
3
Report
YMF808
·2022-03-31
Cool
Reply
4
Report
Verine
·2022-03-31
Nice
Reply
2
Report
Seah CL
·2022-03-31
K
Reply
1
Report
adonis123
·2022-03-31
DYODD
Reply
2
Report
AK1228
·2022-03-31
Plz like
Reply
1
Report
YJ Lee
·2022-03-31
Ok
Reply
1
Report
kahhin
·2022-03-31
Yo
Reply
2
Report
SPOT_ON
·2022-03-31
Nice
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2223092538?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-03-30 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2223092538","market":"us","top_or_hot":-1,"title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","media":"Motley Fool","content":"<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLUG","symbol_name":"普拉格能源","start_time":0,"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","article_id":"2223092538","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","pubTimestamp":1648644301,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLUG":"普拉格能源","OCGN":"Ocugen","RIVN":"Rivian Automotive, Inc."},"translate_title":"华尔街数据显示，3只成长型股票上涨幅度高达331%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9,"PLUG":0.9,"RIVN":0.9},"content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9013135545,"gmtCreate":1648689651465,"gmtModify":1676534379985,"author":{"id":"3582502134655895","authorId":"3582502134655895","name":"Bspn","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582502134655895","authorIdStr":"3582502134655895"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013135545","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013342548,"gmtCreate":1648687222688,"gmtModify":1676534378869,"author":{"id":"3568944508199908","authorId":"3568944508199908","name":"saral","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3568944508199908","authorIdStr":"3568944508199908"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013342548","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013358431,"gmtCreate":1648686706524,"gmtModify":1676534378426,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"okay","listText":"okay","text":"okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013358431","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013334986,"gmtCreate":1648684308658,"gmtModify":1676534377262,"author":{"id":"4092698747642690","authorId":"4092698747642690","name":"WaiSiong81","avatar":"https://static.tigerbbs.com/81c10c8d3ad2387a719eaa62a541371f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4092698747642690","authorIdStr":"4092698747642690"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013334986","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013952548,"gmtCreate":1648681634187,"gmtModify":1676534375906,"author":{"id":"4087771643270940","authorId":"4087771643270940","name":"seojun","avatar":"https://static.tigerbbs.com/3bd9ce06b0a58d0a81582641f6566970","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4087771643270940","authorIdStr":"4087771643270940"},"htmlText":"Green energy seems like way to go!","listText":"Green energy seems like way to go!","text":"Green energy seems like way to go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013952548","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013953309,"gmtCreate":1648681441954,"gmtModify":1676534375800,"author":{"id":"3586393315819735","authorId":"3586393315819735","name":"Vincent1968","avatar":"https://community-static.tradeup.com/news/7f106edb1e06baf3c68462c050422f46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586393315819735","authorIdStr":"3586393315819735"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013953309","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013926492,"gmtCreate":1648681136450,"gmtModify":1676534375654,"author":{"id":"3582011723925907","authorId":"3582011723925907","name":"Rick13","avatar":"https://static.tigerbbs.com/2d3e47faeb6cb380146cd4f1415c29cf","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3582011723925907","authorIdStr":"3582011723925907"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013926492","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013969408,"gmtCreate":1648680167847,"gmtModify":1676534375212,"author":{"id":"3571345352614779","authorId":"3571345352614779","name":"xiaobaii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3571345352614779","authorIdStr":"3571345352614779"},"htmlText":"like &amp; comment please&nbsp;","listText":"like &amp; comment please&nbsp;","text":"like & comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013969408","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013989331,"gmtCreate":1648679423931,"gmtModify":1676534374961,"author":{"id":"3584157491931754","authorId":"3584157491931754","name":"bostonxsgp","avatar":"https://static.tigerbbs.com/55d82efabeabddb18cc2d6ca7a71a36f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584157491931754","authorIdStr":"3584157491931754"},"htmlText":"meh","listText":"meh","text":"meh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013989331","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013915531,"gmtCreate":1648679125247,"gmtModify":1676534374750,"author":{"id":"3577580458147788","authorId":"3577580458147788","name":"fysx49","avatar":"https://static.tigerbbs.com/fe5937c0ada861e9603ef8a12ae3e445","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3577580458147788","authorIdStr":"3577580458147788"},"htmlText":"Market start recovering","listText":"Market start recovering","text":"Market start recovering","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013915531","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013937940,"gmtCreate":1648678218005,"gmtModify":1676534374542,"author":{"id":"4101948424484190","authorId":"4101948424484190","name":"Success88","avatar":"https://static.itradeup.com/news/4408e1a22d73e99adb53aa65dde8ad91","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"4101948424484190","authorIdStr":"4101948424484190"},"htmlText":"Yes great&nbsp;","listText":"Yes great&nbsp;","text":"Yes great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013937940","repostId":2223092538,"repostType":2,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013932981,"gmtCreate":1648677970691,"gmtModify":1676534374489,"author":{"id":"4087535772132840","authorId":"4087535772132840","name":"SS3006","avatar":"https://community-static.tradeup.com/news/e9bb9a1e79b4a0ebd6fcef48ef3207c5","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"4087535772132840","authorIdStr":"4087535772132840"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013932981","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013931182,"gmtCreate":1648677543962,"gmtModify":1676534374419,"author":{"id":"4087173082353320","authorId":"4087173082353320","name":"YMF808","avatar":"https://static.tigerbbs.com/4baafafa8982b2c0a7b4c828a5e3cbfb","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087173082353320","authorIdStr":"4087173082353320"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013931182","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013930269,"gmtCreate":1648677150835,"gmtModify":1676534374371,"author":{"id":"4098528367477030","authorId":"4098528367477030","name":"Verine","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":3,"crmLevelSwitch":0,"idStr":"4098528367477030","authorIdStr":"4098528367477030"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013930269","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013997903,"gmtCreate":1648676903815,"gmtModify":1676534374316,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4102135564535180","authorIdStr":"4102135564535180"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013997903","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013994572,"gmtCreate":1648676836953,"gmtModify":1676534374324,"author":{"id":"4087116753605820","authorId":"4087116753605820","name":"adonis123","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":3,"crmLevelSwitch":0,"idStr":"4087116753605820","authorIdStr":"4087116753605820"},"htmlText":"DYODD","listText":"DYODD","text":"DYODD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013994572","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013994159,"gmtCreate":1648676776434,"gmtModify":1676534374299,"author":{"id":"4092725445650230","authorId":"4092725445650230","name":"AK1228","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"4092725445650230","authorIdStr":"4092725445650230"},"htmlText":"Plz like","listText":"Plz like","text":"Plz like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013994159","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013995129,"gmtCreate":1648676660769,"gmtModify":1676534374283,"author":{"id":"4108816210230400","authorId":"4108816210230400","name":"YJ Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4108816210230400","authorIdStr":"4108816210230400"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013995129","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013992742,"gmtCreate":1648676629179,"gmtModify":1676534374268,"author":{"id":"3571436988972218","authorId":"3571436988972218","name":"kahhin","avatar":"https://community-static.tradeup.com/news/909be99fb530350c25cf265ff64f3698","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3571436988972218","authorIdStr":"3571436988972218"},"htmlText":"Yo","listText":"Yo","text":"Yo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013992742","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9013905870,"gmtCreate":1648675198107,"gmtModify":1676534373900,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":1,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9013905870","repostId":2223092538,"repostType":4,"repost":{"id":"2223092538","pubTimestamp":1648644301,"share":"https://ttm.financial/m/news/2223092538?lang=&edition=fundamental","pubTime":"2022-03-30 20:45","market":"us","language":"en","title":"3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2223092538","media":"Motley Fool","summary":"Select analysts believe these fast-paced stocks can soar over the next 12 months.","content":"<html><head></head><body>KEY POINTS<ul><li>If these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.</li><li>Analysts&#39; lofty price targets often fail to capture the challenges high-growth companies are facing.</li></ul>Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won&#39;t suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.<img src=\"https://static.tigerbbs.com/eb5c43d2584290008d74d267dba12d47\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> boasts the highest price target on Wall Street for Rivian. If Jonas&#39;s $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas&#39;s lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian&#39;s R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that&#39;ll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What&#39;s more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who&#39;d placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn&#39;t look achievable anytime soon.<img src=\"https://static.tigerbbs.com/1abce5caf5e785b826f62bb98ff77b01\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer&#39;s view, Ocugen&#39;s upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it&#39;s commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we&#39;re still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it&#39;s approved, there&#39;s little assurance it&#39;ll be used over other vaccines with higher VEs. LeBoyer&#39;s $15 price target is highly unlikely to be hit.<img src=\"https://static.tigerbbs.com/51b9e73cc74dad844548f15906c23624\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/>Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal&#39;s high-water price target on Plug Power is based on an expansion of the company&#39;s green hydrogen network, and the ongoing deployment of the company&#39;s hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company&#39;s margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe&#39;s light commercial vehicle market. These deals signaled that Plug&#39;s fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug&#39;s ambitions of becoming one of world&#39;s leading green hydrogen ecosystems.While there&#39;s little question that developed countries are pushing for green-energy alternative to fight climate change, it&#39;s not yet clear if Plug Power has the solutions that&#39;ll be preferred. Even at a $28 share price, we&#39;re talking about a company with a greater than $16 billion market cap that&#39;s losing money and hasn&#39;t yet demonstrated if it can handle rapid scaling. This isn&#39;t to say that it won&#39;t be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.</body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-30 20:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are...\n\n<a href=\"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","PLUG":"普拉格能源","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2022/03/30/3-growth-stocks-monster-upside-to-331-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2223092538","content_text":"KEY POINTSIf these high-water price targets are hit, investors would enjoy upside ranging from 179% to 331%.Analysts' lofty price targets often fail to capture the challenges high-growth companies are facing.Over the long run, the stock market has proved to be a wealth-building machine. Even though corrections are commonplace, investors are typically doubling their money about once a decade.But for a select group of high-growth stocks, simply doubling your money in a decade won't suffice. According to the high-water 12-month price targets from a group of Wall Street analysts, the following three supercharged growth stocks offer monster upside ranging from 179% on the low end to as much as 331%.Image source: Getty Images.Rivian Automotive: Implied upside of 218%The first fast-paced company with significant upside potential is the hottest initial public offering (IPO) of 2021, electric vehicle (EV) manufacturer Rivian Automotive. Analyst Adam Jonas of Morgan Stanley boasts the highest price target on Wall Street for Rivian. If Jonas's $147 price target were to hit, it would represent an increase of 218% from where shares ended this past week.Jonas's lofty projection is based on the expectation that Rivian will be producing 1.5 million battery EVs (BEVs) annually by 2030, and will be able to grow its software business from an estimated $641 million in 2025 to approximately $36 billion by 2040 as the installed base of Rivian BEVs grows.Pardon the pun, but the bullishness surrounding Rivian does have some fuel behind it. In 2019, the company secured an order for 100,000 electric vans from e-commerce giant Amazon. Even before becoming a publicly traded company, this order provided some level of validation that Rivian was poised to become a major EV player. Also, keep in mind that Rivian's R1T electric truck looks to be in a class of its own with regard to luxury EV trucks.Additionally, Rivian is sitting on a mountain of capital following its IPO. The company ended 2021 with $18.4 billion in cash and cash equivalents, which is allowing management to aggressively invest in production expansion efforts.  For instance, $5 billion is being spent to build a manufacturing plant in Georgia that'll produce up to 400,000 EVs annually once it begins production in 2024.But betting on Rivian to become a $130 billion company seems like a stretch when supply chain issues have cut expected EV production to 25,000 in 2022 from an estimated 50,000.What's more, rising material costs have put Rivian between a rock and a hard place. Earlier this month, the company announced significant price hikes on its quad-motor models, only to walk back to those hikes on people who'd placed reservations with the company prior to March 1. As EV companies like Nikola and Lordstown Motors have shown, overcoming PR flubs can be very difficult. Suffice it to say, $147 doesn't look achievable anytime soon.Image source: Getty Images.Ocugen: Implied upside of 331%A second high-growth stock with monster upside potential, at least in the eyes of one Wall Street analyst, is small-cap biotech company Ocugen( OCGN 6.87% ). According to Robert LeBoyer of Noble Financial, Ocugen can hit $15 a share, which would represent jaw-dropping upside of 331% from where it closed this past week.In LeBoyer's view, Ocugen's upside is tied to COVID-19 vaccine Covaxin, which in his view holds competitive advantages over other COVID-19 vaccines already in use in North America. The U.S. Food and Drug Administration (FDA) recently removed a partial clinical hold on Covaxin in the U.S., which officially clears a path for Ocugen to submit a biologics licensing application on the drug it's commercially licensed from Bharat Biotech.Last year, Bharat Biotech ran a large-scale study involving Covaxin on 25,800 people in India. That trial produced a vaccine efficacy (VE) of 78%. Considering that there are billions of people worldwide still in need of initial COVID-19 inoculations and/or booster shots, we're still at a stage where new and effective vaccines are welcome on the global stage.The issue for Ocugen is that its commercial agreement with Bharat concerning Covaxin only covers the U.S. and Canada. While these are traditionally high-margin markets, the U.S. and Canada have heavily invested in COVID-19 vaccines. A large percentage of the population for both countries have already been vaccinated and/or received booster shots. Further, new vaccine options with a higher VE than Covaxin are waiting in the wings.To make matters worse, the FDA declined to grant Covaxin a pathway to emergency-use authorization (EUA) for pediatric patients aged 2 to 18. Despite the company announcing that it would continue to work with the FDA on a possible EUA path for pediatric patients, this revenue channel looks to be shut off.Long story short, Ocugen still looks to be a ways away from having any chance of getting Covaxin approved for use in the U.S. -- and even if it's approved, there's little assurance it'll be used over other vaccines with higher VEs. LeBoyer's $15 price target is highly unlikely to be hit.Image source: Getty Images.Plug Power: Implied upside of 179%The third growth stock with salivating upside is hydrogen fuel-cell solutions provider Plug Power. According to H.C. Wainwright analyst Amit Dayal, Plug Power can hit $78 a share, which would represent an increase of 179% from where shares ended this past week.Dayal's high-water price target on Plug Power is based on an expansion of the company's green hydrogen network, and the ongoing deployment of the company's hydrogen fuel-cell-powered GenDrive units. With most markets promoting clean-energy solutions, Dayal anticipates the company's margins will improve across the board.Plug Power really put itself on the map in early 2021 when it struck two major partnerships within a span of one week. In January 2021, SK Group took a 10% equity stake in the company and formed a joint venture to bring fuel-cell solutions (for vehicles and refilling stations) to numerous Asian markets. Roughly a week later, Plug and French auto company Renault forged a joint venture to tackle Europe's light commercial vehicle market. These deals signaled that Plug's fuel-cell solutions were about more than just powering forklifts in warehouses.The company has also signaled its willingness to be a key next-gen energy player with acquisitions. In December, it completed its buyout of green hydrogen solutions company Frames Group, which furthers Plug's ambitions of becoming one of world's leading green hydrogen ecosystems.While there's little question that developed countries are pushing for green-energy alternative to fight climate change, it's not yet clear if Plug Power has the solutions that'll be preferred. Even at a $28 share price, we're talking about a company with a greater than $16 billion market cap that's losing money and hasn't yet demonstrated if it can handle rapid scaling. This isn't to say that it won't be able to scale its ecosystem, so much as to point out that its valuation implies everything will go off without a hitch. Rarely is that the case with next-gen technologies and solutions.Although Plug Power is a company people can hope is successful, it has a lot of questions to answer at its current valuation, let alone one that would be 179% higher.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":559,"commentSize":34,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false}}